# Transradial vs Transfemoral Access for Cerebral Angiography: A Randomized Noninferiority Clinical Trial

**Authors:** Wei Ni, Heng Yang, Jiabin Su, Ya Peng, Dengliang Wang, Zhiqing Lin, Jun Sun, Xuelin Chen, Jiyue Wang, Yi Li, Jiaxiong Wang, Shu Wan, Xin Ye, Qingrong Zhang, Donghai Wang, Chao Gao, Hanqiang Jiang, Xinjie Gao, Yingying Zhang, Bing Han, Jie Cao, Xucheng Zhu, Shengjun Zhou, Yiyong Zeng, Fuxiang Chen, Yuanxiang Lin, Huajun Ba, Xiaoxiang Chen, Xianglu Liu, Jiheng Hao, Zhaoliang Sun, Mei Li, Ming Wang, Dajiang Xie, Zong Zhuang, Lin Shi, Liang Zhou, Hongyu Tang, Dan Chen, Craig S. Anderson, Dezhi Kang, Yuxiang Gu

PMC · DOI: 10.1001/jamanetworkopen.2026.1929 · 2026-03-19

## TL;DR

A clinical trial found that transradial access is not as effective as transfemoral access for cerebral angiography, despite shorter recovery times and less pain.

## Contribution

This study is the first randomized clinical trial comparing transradial and transfemoral access for diagnostic cerebral angiography.

## Key findings

- Transradial access had a lower success rate for diagnostic cerebral angiography compared to transfemoral access.
- Transradial access resulted in shorter time in bed and lower pain scores than transfemoral access.
- TRA had more radial artery puncture failures compared to TFA.

## Abstract

Is transradial access (TRA) noninferior to transfemoral access (TFA) in efficacy and safety for diagnostic cerebral angiography?

In this randomized clinical trial including 858 patients, the success rate for accuracy in diagnostic cerebral angiography was lower in the TRA group (91%) compared with the TFA group (96%) and did not meet the prespecified noninferiority margin.

TRA was not noninferior to TFA for diagnostic cerebral angiography.

This randomized clinical trial compares the safety and efficacy of transradial access with that of transfemoral access for patients undergoing diagnostic cerebral angiography.

Transradial access (TRA) has emerged as a promising alternative to standard transfemoral access (TFA) for interventional cardiac procedures, but its application for examination of the cerebral circulation has not been tested in a clinical trial.

To compare the efficacy and safety of TRA with TFA for diagnostic cerebral angiography.

This investigator-initiated, multicenter, open-label, noninferiority randomized clinical trial with a blinded outcome assessment was conducted at 13 sites in China. Patients eligible for cerebral angiography were randomized between September 15, 2023, and November 4, 2024, with final follow-up performed on November 27, 2024. The primary analysis was performed in the intention-to-treat population; secondary analyses were performed in the per-protocol population.

Patients were randomly allocated to TRA (n = 431) or TFA (n = 430) for diagnostic cerebral angiography.

The primary outcome was the success of diagnostic cerebral angiography. Secondary outcomes were success in achieving an accurate diagnosis, duration of angiography and fluoroscopy, time in bed, and patient-reported satisfaction on an 11-point visual analog scale for pain (ranging from 0 [none] to 10 [worst possible]) within 24 hours after the procedure. The noninferiority margin was an absolute difference of 5% in success of angiographic diagnosis and success of accurate diagnosis.

A total of 858 patients (median age, 58.4 [IQR, 52.0-67.0] years; 479 [55.8%] male) completed the trial. Success of diagnostic cerebral angiography in the TRA group was lower than that in the TFA group (392 of 431 [91.0%] vs 409 of 427 [95.8%]; difference, −4.8 percentage points [pp] [95% CI, −8.1 to −1.5 pp]; relative risk [RR], 0.95 [95% CI, 0.92-0.98]; P = .46 for noninferiority test). The success rate of accurate diagnosis was 78.9% in the TRA group vs 91.1% in the TFA group (difference, −12.2 pp [95% CI, −16.9 to −7.5 pp]; RR, 0.87 [95% CI, 0.82-0.92]; P = .99 for noninferiority test). Compared with the TFA group, the TRA group had longer median times for angiography (33.7 [IQR, 23.0-40.0] vs 38.7 [IQR, 26.0-47.0] minutes; P < .001) and fluoroscopy (10.6 [IQR, 5.6-12.9] vs 11.8 [IQR, 6.2-15.0] minutes; P = .02); the TRA group had significantly shorter median time in bed (188.4 [IQR, 3.0-180.0] vs 1079.0 [IQR, 842.0-1366.0] minutes; P < .001) and lower median pain scores (0.5 [IQR, 0.0-1.0] vs 0.7 [IQR, 0.0-1.0]; P < .001). Overall angiography complications were comparable between the groups (19 of 445 [4.3%] vs 25 of 413 [6.1%]; P = .28), but TRA had more radial artery puncture failures than TFA.

In this randomized clinical trial of patients undergoing diagnostic cerebral angiography, TRA was not shown to be noninferior to TFA with regard to the success rate of diagnostic cerebral angiography. Additional research, including superiority trials, is needed to clearly define the comparative benefits of TRA and TFA.

ClinicalTrials.gov Identifier: NCT05401669

## Full-text entities

- **Diseases:** hyperlipidemia (MESH:D006949), arterial occlusion (MESH:D001157), blindness (MESH:D001766), contrast encephalopathy (MESH:D001927), artery dissection (MESH:D000094665), femoral nerve injury (MESH:D020428), hypertension (MESH:D006973), bradycardia (MESH:D001919), embolism (MESH:D004617), atherosclerotic plaque (MESH:D058226), fracture (MESH:D050723), bleeding (MESH:D006470), infection (MESH:D007239), femoral artery pseudoaneurysm (MESH:D017541), cerebral infarction (MESH:D002544), vasospasm (MESH:D020301), spasm (MESH:D013035), nerve injury (MESH:D000080902), intracranial hemorrhage (MESH:D020300), hypotension (MESH:D007022), death (MESH:D003643), kidney complications (MESH:D007674), hematoma (MESH:D006406), pain (MESH:D010146), stenosis (MESH:D003251), type III aortic arch (MESH:D001015), compartment syndrome (MESH:D003161), arteriovenous fistula (MESH:D001164), ischemia (MESH:D007511), central nervous system infection (MESH:D002494), venous thromboembolism (MESH:D054556), diabetes (MESH:D003920), neurologic complications (MESH:D002493), artery perforation (MESH:D057112)
- **Chemicals:** TFA (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13003373/full.md

---
Source: https://tomesphere.com/paper/PMC13003373